| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Polatuzumab vedotin-piiq (anti-CD79b)
CAS:1313206-42-6
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K13697
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Polatuzumab Vedotin
CAS:1313206-42-6
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Polatuzumab Vedotin
CAS:1313206-42-6
Purity:>95% Package:100ug;200ug;1mg
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Polatuzumab(DHE26301)
CAS:1313206-42-6
Purity:PAGE:>95% Package:100ug;1mg
|
Polatuzumab vedotin manufacturers
- Polatuzumab vedotin
-
- $2090.00 / 5mg
-
2026-04-20
- CAS:1313206-42-6
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Polatuzumab vedotin Basic information |
| Product Name: | Polatuzumab vedotin | | Synonyms: | Polatuzumab vedotin;Research Grade Polatuzumab(DHE26301);Polatuzumab vedotin-piiq (ADC);Research Grade Polatuzumab;Polatuzumab vedotin-piiq (anti-CD79b) | | CAS: | 1313206-42-6 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Polatuzumab vedotin Structure]() |
| | Polatuzumab vedotin Chemical Properties |
| form | Solid | | color | White to off-white |
| | Polatuzumab vedotin Usage And Synthesis |
| Uses | Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL)[1]. | | Synthesis | The drug was developed by Genentech (a division of Roche) using ADC linker-payload technology licensed and developed by Senter and colleagues at Seagen (formerly Seattle Genetics). This same linker-payload and conjugation strategy was also incorporated into the preparation of Brentuximab Vedotin (approved in 2011) and Enfortumab Vedotin (approved in 2019). Although no clear preparation method for Pelotonuzumab is found in the patent literature, the drug was developed using Seagen technology, and its synthesis process is generally described in the scheme and is very similar to that described for Brentuximab Vedotin, except that slightly different reagents are used.
 | | References | [1] Liebers N, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021 Jul 13;5(13):2707-2716. DOI:10.1182/bloodadvances.2020004155
[2] Li D, et al. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin. Br J Pharmacol. 2019 Oct;176(19):3805-3818. DOI:10.1111/bph.14784 |
| | Polatuzumab vedotin Preparation Products And Raw materials |
|